Physician profile
Roy Barco
NPI 1033436191
$8,228.77
in general payments reported to CMS, 2019-2025
45 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $717 · 2021: $1,251 · 2022: $1,423 · 2023: $1,253 · 2024: $1,746 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,559.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,353.03 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $889.77 | 2020-2025 | Relistor, Xifaxan, Trulance |
| Lilly USA, LLC | $769.76 | 2020-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $389.21 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Indivior INC. | $367.22 | 2019-2025 | Sublocade |
| Pfizer INC. | $300.92 | 2019-2025 | |
| Novo Nordisk INC | $291.84 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $256.34 | 2023-2025 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $247.59 | 2021-2024 | Ztlido |
| Otsuka America Pharmaceutical, INC. | $212.87 | 2023-2025 | Rexulti |
| Amgen INC. | $194.96 | 2019-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.43 | 2022-2025 | Caplyta |
| Gilead Sciences, INC. | $157.75 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $125.41 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $124.56 | 2023-2025 | Auvelity, Sunosi |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Barco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.